Avanafil and Riociguat: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
A soluble-guanylate-cyclase stimulator and a PDE5 inhibitor can cause excessive blood-pressure lowering.
Clinical significance and safety
Avanafil and Riociguat: Riociguat and a PDE5 inhibitor must not be combined: the product information contraindicates concurrent use because of hypotension. Switching requires a specialist-controlled plan and an appropriate treatment-free interval. Do not combine or switch them yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.